Rockefeller Capital Management
VRDN icon

Rockefeller Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Rockefeller Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.5K Buy
1,663
+510
+44% +$15.1K ﹤0.01% 3480
2025
Q4 		$35.9K Buy
1,153
+133
+13% +$3.65K ﹤0.01% 3226
2025
Q3 		$22K Buy
+1,020
New +$18.4K ﹤0.01% 3314

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Rockefeller Capital Management's VRDN Position: Q1 2026 in Review

Rockefeller Capital Management increased its Viridian Therapeutics (VRDN) stake by 44% in Q1 2026, buying an estimated $15.1K and bringing the position to 1,663 shares worth $32.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3480.

Rockefeller Capital Management first reported a position in VRDN in Q3 2025 and has held it in 3 quarters since. The position peaked at $35.9K in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Rockefeller Capital Management held 1,663 shares of Viridian Therapeutics worth $32.5K as of Q1 2026.
  • Rockefeller Capital Management bought 510 Viridian Therapeutics shares in Q1 2026, an estimated $15.1K.
  • Viridian Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3480 holding.
  • Rockefeller Capital Management first reported a position in Viridian Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Rockefeller Capital Management's Viridian Therapeutics position peaked at $35.9K in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.